Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas Program covers scientific rationale, preclinical...
Company to host a webcast at 9:00am ET / 6:00am PT...
Corvus to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. ...
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT...
BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage...
Data Presented in Poster Presentation at American Society of Hematology Annual Meeting...
Results in patients with relapsed refractory NSCLC and head and neck cancer demonstrate tumor reduction in patients treated with mupadolimab mono and...
BURLINGAME, Calif. (AP) _ Corvus Pharmaceuticals Inc. (CRVS) on Monday reported a loss of $10.7 million in its third quarter.
BURLINGAME, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today...
CPI-818 clinical trial in China will be conducted by Angel Pharmaceuticals...